BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abdul-Latif M, Townsend K, Dearman C, Shiu KK, Khan K. Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives. Cancer Treat Rev 2020;88:102030. [PMID: 32505807 DOI: 10.1016/j.ctrv.2020.102030] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Hu Y, Chen C, Tong X, Chen S, Hu X, Pan B, Sun X, Chen Z, Shi X, Hu Y, Shen X, Xue X, Lu M. NSUN2 modified by SUMO-2/3 promotes gastric cancer progression and regulates mRNA m5C methylation. Cell Death Dis 2021;12:842. [PMID: 34504059 DOI: 10.1038/s41419-021-04127-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hu BS, Tang T, Jia JL, Xie BC, Wu TL, Sheng YY, Xue YZ, Tang HM. CD137 agonist induces gastric cancer cell apoptosis by enhancing the functions of CD8+ T cells via NF-κB signaling. Cancer Cell Int 2020;20:513. [PMID: 33093811 DOI: 10.1186/s12935-020-01605-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Lu Z, Peng Z, Liu C, Wang Z, Wang Y, Jiao X, Li J, Shen L. Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers. Innovation (N Y) 2020;1:100041. [PMID: 34557714 DOI: 10.1016/j.xinn.2020.100041] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Sumransub N, Vantanasiri K, Prakash A, Lou E. Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success? Mol Ther Oncolytics 2021;22:1-12. [PMID: 34307839 DOI: 10.1016/j.omto.2021.05.001] [Reference Citation Analysis]
5 Angerilli V, Galuppini F, Businello G, Dal Santo L, Savarino E, Realdon S, Guzzardo V, Nicolè L, Lazzarin V, Lonardi S, Loupakis F, Fassan M. MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors. Biomedicines 2021;9:318. [PMID: 33801049 DOI: 10.3390/biomedicines9030318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Bolandi N, Derakhshani A, Hemmat N, Baghbanzadeh A, Asadzadeh Z, Afrashteh Nour M, Brunetti O, Bernardini R, Silvestris N, Baradaran B. The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment. Int J Mol Sci 2021;22:10719. [PMID: 34639059 DOI: 10.3390/ijms221910719] [Reference Citation Analysis]
7 Wang J, Wei B, Thakur K, Wang CY, Li KX, Wei ZJ. Transcriptome Analysis Reveals the Anti-cancerous Mechanism of Licochalcone A on Human Hepatoma Cell HepG2. Front Nutr 2021;8:807574. [PMID: 34988109 DOI: 10.3389/fnut.2021.807574] [Reference Citation Analysis]
8 Couvineau A, Voisin T, Nicole P, Gratio V, Blais A. Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions. World J Gastroenterol 2021; 27(44): 7582-7596 [PMID: 34908800 DOI: 10.3748/wjg.v27.i44.7582] [Reference Citation Analysis]
9 Alain C, Pascal N, Valérie G, Thierry V. Orexins/Hypocretins and Cancer: A Neuropeptide as Emerging Target. Molecules 2021;26:4849. [PMID: 34443437 DOI: 10.3390/molecules26164849] [Reference Citation Analysis]
10 Chudasama R, Phung Q, Hsu A, Almhanna K. Vaccines in Gastrointestinal Malignancies: From Prevention to Treatment. Vaccines (Basel) 2021;9:647. [PMID: 34199248 DOI: 10.3390/vaccines9060647] [Reference Citation Analysis]
11 Songjang W, Nensat C, Pongcharoen S, Jiraviriyakul A. The role of immunogenic cell death in gastrointestinal cancer immunotherapy (Review). Biomed Rep 2021;15:86. [PMID: 34512974 DOI: 10.3892/br.2021.1462] [Reference Citation Analysis]
12 Wang J, Wang CY. Integrated miRNA and mRNA omics reveal the anti-cancerous mechanism of Licochalcone B on Human Hepatoma Cell HepG2. Food Chem Toxicol 2021;150:112096. [PMID: 33647349 DOI: 10.1016/j.fct.2021.112096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Mazloom A, Ghalehsari N, Gazivoda V, Nimkar N, Paul S, Gregos P, Rateshwar J, Khan U. Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies. J Clin Med 2020;9:E2533. [PMID: 32781500 DOI: 10.3390/jcm9082533] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
14 Mandriani B, Pelle' E, Pezzicoli G, Strosberg J, Abate-Daga D, Guarini A, Cives M, Porta C. Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives. Cancer Treat Rev 2021;100:102288. [PMID: 34525422 DOI: 10.1016/j.ctrv.2021.102288] [Reference Citation Analysis]
15 Chen Y, Long W, Yang L, Zhao Y, Wu X, Li M, Du F, Chen Y, Yang Z, Wen Q, Yi T, Xiao Z, Shen J. Functional Peptides Encoded by Long Non-Coding RNAs in Gastrointestinal Cancer. Front Oncol 2021;11:777374. [PMID: 34888249 DOI: 10.3389/fonc.2021.777374] [Reference Citation Analysis]